Use of direct thrombin inhibitors in acute coronary syndrome

Clinical Therapeutics

Volumn 22, Issue 8, 2000, Pages 937-948

  Nemergut, Christopher ^a   Cheng, Judy W M ^a,b  

^a LONG ISLAND UNIVERSITY   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Direct thrombin inhibitors; Refractory angina; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; DESULFATOHIRUDIN; HEPARIN; HIRULOG; LEPIRUDIN; STREPTOKINASE; THROMBIN; THROMBIN INHIBITOR;

ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CORONARY ARTERY; DRUG EFFICACY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; THROMBOCYTOPENIA; THROMBOGENESIS;

EID: 0033851768     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80065-X     Document Type: Article

References (20)

1. Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction
2. Primary prevention of coronary heart disease: Guidance from Framingham: A statement for healthcare professionals from the AHA Task Force on Risk Reduction
3. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
4. Effects of recombinant hirudin (lepirudin) compared to heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: A randomized trial
5. Randomized, double-blinded comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction
6. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
7. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina
8. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndrome
9. Hirudin in acute myocardial infarction
10. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation
11. Insights into the pathogenesis of acute ischemic syndromes
12. New antithrombotic agents
13. The pathogenesis of coronary artery disease and the acute coronary syndrome
14. Molecular and cellular biology of blood coagulation
15. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin
16. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
17. Modulation of thrombin and heparin activities by fibrin
18. Thrombin inhibitors as anticoagulant agents
19. Antithrombin agents as anticoagulants and antithrombotics: Implications in drug development
20. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: Results of the HIT-4 trial